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S-2-hydroxyglutarate regulates CD8+ 
T-lymphocyte fate
Petros A. Tyrakis1,2, Asis Palazon1, David Macias1, Kian. L. Lee4, Anthony. T. Phan3, Pedro Veliça5, Jia You4, Grace S. Chia4, 
Jingwei Sim1, Andrew Doedens3, Alice Abelanet1, Colin E. Evans1, John R. Griffiths2, Lorenz Poellinger4,5, Ananda. W. Goldrath3 
& Randall S. Johnson1,5
In response to T-cell receptor (TCR) triggering, quiescent CD8+ 
T-lymphocytes transition to a proliferative effector state. During this 
response, memory CD8+ T-lymphocytes form and can persist for the 
life of the organism, mounting rapid recall responses thereby providing 
long-term immunity. The metabolic programs of these different CD8+ 
T-lymphocyte states are distinct and important for function1-4. Effector 
CD8+ T-lymphocytes generate most ATP and biomass via glycolysis5; 
both naïve and memory cells rely heavily on oxidative phosphorylation 6,7. 
Various cytokines and transcription factors are important for the differ-
entiation of CD8+ T-lymphocytes, and it is evident that immunological 
memory is influenced by epigenetic mechanisms8-12.
CD8+ T-lymphocytes traffic into severely hypoxic zones within 
tumours and inflammatory tissue13. The response to oxygenation 
mediated via the Von Hipple Lindau (VHL) and hypoxia inducible 
transcription factor α (HIFα ) proteins, is an essential regulator of 
metabolism and CD8+ T-lymphocyte function14-16. Here we demon-
strate that CD8+ T-lymphocytes produce 2-hydroxyglutarate (2HG) in 
response to TCR triggering and environmental hypoxia. Using CD8+ 
T-lymphocyte specific genetic deletions of VHL, HIF-1α and HIF-2α , 
we highlight the dependency of this metabolic feature on the HIF path-
way. S-2HG constitutes the majority of the 2HG pool and we show that 
S-2HG alters the phenotypic and functional characteristics of CD8+ 
T-lymphocytes, maintaining a state of increased proliferative, survival 
and anti-tumour capacity.
The VHL-HIF-1α axis regulates 2HG production
To elucidate metabolic effects of HIFα activation, we profiled the 
metabolome of CD8+ T-lymphocytes with low (Vhlfl/fl), or high (Vhlfl/fl 
dlckcre referred to as Vhl-/-) HIF signalling, and HIF-1α -VHL double 
knockouts (Hif1αfl/flVhlfl/fldlckcre referred to as Hif1α -/-Vhl-/-) to control 
for a specific contribution of HIF-1α 14. Unsupervised clustering and 
principal component analysis (Fig. 1a, b) separate Vhl-/- from Vhlfl/fl  
CD8+ T-lymphocytes. Vhl-/-Hif1α -/- cluster with Vhlfl/fl, indicating that 
HIF-1α mediates significant metabolic changes following Vhl deletion. 
Glycolysis is critical for sustaining effector function1-3,17 and these 
data indicate that VHL suppresses glycolysis via inhibition of HIF-1α , 
(Extended Data Fig. 1a-c).
VHL loss suppresses late and increases early tricarboxylic acid 
(TCA) cycle intermediates (Extended Data Fig. 1a). Strikingly, 2HG 
is significantly enriched in Vhl-/- CD8+ T-lymphocytes (Fig. 1c and 
Extended Data Fig. 1d). Furthermore, increases in 2HG depend on 
HIF-1α when VHL is deleted (Extended Data Fig. 1a). This was vali-
dated using quantitative mass spectrometry in Vhl-/- and Vhl-/-Hif1-/- 
CD8+ T-lymphocytes (Fig. 1d), as well as in VHL-null cell lines, that 
express either HIF-1α (RCC4) or HIF-2α (786-O), reconstituted with 
VHL (Fig. 1e and Extended Data Fig. 1e). Deletion of Vhl in murine 
embryonic fibroblasts from Vhlfl/fl mice increases 2HG levels (Fig. 1f 
and Extended Data Fig. 1f). Hence, the VHL-HIF axis regulates 
2HG levels and constitutive HIF-1α signalling underlies this effect in 
Vhl-null CD8+ T-lymphocytes.
HIF-1α regulates S-2HG production
R-2HG is produced by isocitrate dehydrogenase 1/2 mutations in 
different cancers18-20; accumulation of S-2HG, the other enantiomer 
of 2HG, occurs in the context of hypoxia21,22 and mitochondrial 
dysfunction23,24. We thus sought to determine 2HG levels in CD8+ 
T-lymphocytes following activation. 2HG before activation and at sea 
level oxygen is undetectable, whereas levels at the same oxygenation 
are elevated 2-4 days after TCR stimulation (Fig. 2a).When activated 
CD8+ T-lymphocytes are exposed to 1% oxygen, the intracellular 
concentration of 2HG reaches millimolar levels (Fig. 2b and Extended 
Data Fig. 2a) and is proportional to the degree of oxygenation (Fig. 2c). 
We confirmed this using 1HNMR spectroscopy (Extended Data Fig. 2b). 
Given such high levels of 2HG, we sequenced25 Idh1/2, to pre-
clude the unlikely possibility that culturing primary murine CD8+ 
T-lymphocytes in hypoxia gives rise to mutations known to cause 
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function remains elusive. Here we show that CD8+ T-lymphocytes accumulate 2-hydroxyglutarate in response to T-cell 
receptor triggering. This increases to millimolar levels in physiological oxygen conditions, via a hypoxia inducible factor 
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R-2HG production in humans18; we found no evidence for such 
mutations (Extended Data Fig. 3a-e). Resolving the enantiomers of 
2HG indicates that S-2HG constitutes the majority of the 2HG pool 
(Fig. 2d). Primary human CD8+ T-lymphocytes also accumulate 
S-2HG in hypoxia (Fig. 2e, f), indicating that this phenomenon is not 
limited to murine lymphocytes.
We carried out deletion of loxP-flanked Hif1α or Epas1 (referred to as 
Hif2α) genes in CD8+ T-lymphocytes, with cre recombinase expressed 
under the distal Lck promoter (dlckcre)26 (Extended Data Fig. 2c). 2HG 
accumulation is abolished in Hif1αfl/fl dlckcre (referred to as Hif1α-/-), 
but not Hif2αfl/fl dlckcre (referred to as Hif2α-/-) cells under hypoxia 
(Fig. 2g, h and Extended Data Fig. 2d, e), with no difference in viabil-
ity (Extended Data Fig. 2f). We next examined 2HG levels in vivo, in 
the murine spleen. There is more R-2HG than S-2HG (Fig. 2i); fur-
thermore, the levels of S-2HG are significantly decreased in spleens of 
Hif1αfl/fl dlckcre mice (Fig. 2i), There is also a slight decrease in the levels 
of R-2HG (Fig. 2i). 2HG is present in urine of healthy individuals and 
is elevated in patients with 2HG acidurias27. Hif1αfl/fl dlckcre mice have 
lower levels of S-2HG in urine (Fig. 2j) indicating that HIF-1α in the 
T-lymphocyte (CD4+ and CD8+) compartment makes a contribution 
to S-2HG production in vivo. Activated Hif1α-/- CD8+ T-lymphocytes 
in 21% oxygen have lower 2HG at extended time points (Extended 
Data Fig. 2g), indicating a contribution of HIF-1α in non-hypoxic 
conditions also.
We next sought to determine the metabolic route by which HIF-1α 
promotes S-2HG production in CD8+ T-lymphocytes. Transcriptionally, 
hypoxic CD8+ T-lymphocytes show induction of glycolysis and 
suppression of the TCA cycle (Extended Data Fig. 2h). Moreover, 
TCA cycle intermediates are decreased (Extended Data Fig. 2i). 
Recent reports implicate lactate and malate dehydrogenases (Ldha and 
Mdh1/2), as enzymatic sources of S-2HG in hypoxia21,22. In Hif1α-/- 
CD8+ T-lymphocytes, the hypoxic expression of these enzymes 
suggests that Mdh1 and Mdh2 are unlikely to mediate the hypoxia- 
induced accumulation of S-2HG (Extended Data Fig. 2j). Confirming 
this, knockdown of Mdh1 or Mdh2 does not decrease S-2HG in hypoxia 
(Extended Data Fig. 2k-m); knockdown of Mdh1 leads to marginal 
increases in S-2HG (Extended Data Fig. 2l). Knockdown of Mdh1 or 
Mdh2 increases R-2HG levels (Extended Data Fig. 2l, m). Knockdown 
of Ldha (Extended Data Fig. 2k) decreases S-2HG (Fig. 2k), whilst 
also increasing R-2HG levels in hypoxic CD8+ T-lymphocytes 
(Extended Data Fig. 2n).Over-expression of Ldha in hypoxic Hif1α-
/- CD8+ T-lymphocytes (Extended Data Fig. 2o) rescues S-2HG 
production (Fig. 2l). Consistent with this, Ldha expression in 
hypoxic CD8+ T-lymphocytes is HIF-1α -dependent (Extended Data 
Fig. 2j).
We next performed 13C-labelling experiments and in agreement 
with previous reports21,23, U-13C-glucose and U-13C-glutamine trac-
ing indicates that glutamine is the major source of 2HG, (Fig. 2m, 
Extended Data Fig 4a-c). The m+ 5 isotopologue dominates, suggest-
ing direct conversion of glutamine-derived 2-oxoglutarate to 2HG23,21. 
Furthermore, the glutamate pool increases in hypoxic (Extended Data 
Fig. 2p) and Vhl-/- CD8+ T-lymphocytes (Extended Data Fig. 1a) and 
depends on HIF-1α (Extended Data Fig. 2q) but not HIF-2α (Extended 
Data Fig. 2r). Inhibition of pyruvate dehydrogenase (Pdh) by pyru-
vate dehydrogenase kinases (Pdk), promotes glutaminolysis28-30. We 
reasoned that Pdk supports S-2HG production by diverting glutamine- 
derived 2-oxoglutarate to Ldha, and consistent with this, dichloroacetate 
(D A) abrogates hypoxia-induced 2HG accumulation (Extended 
Data Fig. 2s-u). Pdk1 expression is impaired in hypoxic Hif1α-/- CD8+ 
T-lymphocytes (Extended Data Fig. 2j), as is phosphorylation of 
Pdh (Extended Data Fig. 2s), and re-expression of Pdk1 in this con-
text increases S-2HG in hypoxia (Fig. 2l and Extended Data Fig. 2o). 
Inhibition of Pdk activity also impedes hypoxia-induced increases in 
the glutamate pool (Extended Data Fig. 2v). Hence, HIF-1α drives 
S-2HG production in hypoxic CD8+ T-lymphocytes via the Pdk-Pdh 
axis and Ldha induction (Extended Data Fig. 4a).
S-2HG alters CD8+ T-cell differentiation
S-2HG inhibits 2-oxoglutarate-dependent dioxygenases31,32. Consistent 
with this, HIF-1α is stabilized in normoxic (Extended Data Fig. 5a) 
and hypoxic (Extended Data Fig. 5b) CD8+ T-lymphocytes by treat-
ment with cell permeable S-2HG, suggesting that S-2HG augments 
HIF signalling in normoxia and hypoxia. Additionally, there is 
increased phosphorylation of PDH-E1α (Extended Data Fig. 5a and b), 
elevated glucose uptake, lactate secretion (Extended Data Fig. 5c) 
and VEGF-A production (Extended Data Fig. 5d), indicating HIF-1α 
-dependent effects. Since HIF-1α supports effector functions in CD8+ 
T-lymphocytes13,15, we reasoned that S-2HG promotes effector differ-
entiation via HIF-1α . However, unexpectedly, there is suppression of 
effector cytokine production (Extended Data Fig. 5e) and decreased 
cytotoxicity (Extended Data Fig. 5f). Furthermore, S-2HG restrains 
cell expansion (Extended Data Fig. 5g) and there is a clear increase in 
apoptosis at doses > 300 μ M (Extended Data Fig. 5h and i). Further 
characterization reveals decreased secretion of IFN-γ (Extended Data 
Fig. 5j), yet elevated production of IL-2 (Fig. 3a), with increased via-
bility in the absence of IL-2 supplementation (Extended Data Fig. 5k). 
This possibly reflects an autocrine pro-survival effect. These effects are 
robustly mediated at the transcriptional level after prolonged treatment 
with S-2HG (Fig. 3b. Extended Data Fig. 5l) and are independent of 
HIF-1α (Fig. 3a and Extended Data Fig 5j and k).
We then characterized the phenotype of cells treated with a prolonged 
course of S-2HG. There is increased expression of CD62L (Fig. 3c  
and Extended Data Fig. 5m) and this is reversible upon withdrawal 
of treatment (Extended Data Fig. 5n).The effect does not occur when 
treating cells cultured in vehicle for 7 days (Extended Data Fig. 5n), 
demonstrating that S-2HG treatment of newly activated cells main-
tains this phenotypic marker. Importantly, CD62L downregulation does 
not occur when HIF-1α is absent15, masking the effect of S-2HG on 
CD62L following HIF-1α deletion (Extended Data Fig. 5o). HIF-2α is 
dispensable for CD62L maintenance in response to S-2HG (Extended 
Data Fig. 5p). With S-2HG, CD62L maintenance depends on the level 
of antigenic stimulation (Fig. 3d). Furthermore, S-2HG treated cells 
express more CD127 (Fig. 3c), CD44, 41BB, Eomes and less PD-1 in a 
HIF-1α -independent manner (Extended Data Fig. 5q).
To determine the role of endogenously produced S-2HG, over- 
expression of L2hgdh (Extended Data Fig. 5r), a dehydrogenase that 
oxidizes S-2HG, was performed. Over-expression of L2hgdh promotes 
the downregulation of CD62L in both 21% and 1% oxygen (Fig. 3e) 
indicating that endogenously produced S-2HG regulates CD62L expres-
sion. Furthermore, L2hgdh over-expression leads to an increase in the 
proportion of KLRG1High cells, which are decreased in the presence 
of exogenous S-2HG (Fig. 3f). Conversely, successful shRNA-mediated 
knockdown of L2hgdh by hairpin #3 (Extended Data Fig. 5s) increases 
endogenous S-2HG levels (Fig. 3g), especially in 1% oxygen, promoting 
maintenance of CD62L (Fig. 3h). Suppression of L2hgdh blocks loss of 
CD62L in response to low oxygen (Fig. 3h). The same effect is seen with 
CD127 in low oxygen (Extended Data Fig. 5t). These data demonstrate 
that L2hgdh activity regulates the expression of key phenotypic makers 
of CD8+ T-lymphocytes, by controlling endogenous S-2HG levels. 
Transcriptionally, S-2HG treatment increases expression of Eomes, 
Ccr6, Bcl-6, CD62L and Tcf-7, with repression of Prdm1, after 7 days 
(Extended Data Fig. 5u). This transcriptional program is similar to gene 
expression changes in memory CD8+ T-lymphocytes, suggesting that 
S-2HG treatment of CD8+ T-lymphocytes ex vivo may enhance long 
term persistence and survival in the context of adoptive cell transfer33.
We thus co-transferred CFSE-labelled vehicle and S-2HG treated 
CD45.1.1 or CD45.1.2 OT-I CD8+ T-lymphocytes into lymphodepleted 
mice (Extended Data Fig. 6a) to assess their capacity for homeostatic 
proliferation34,35. S-2HG-treated cells display greater homeostatic pro-
liferation (Fig. 4a, b), with more cells dividing > 5 times (Fig. 4c).We 
then assessed the capacity of S-2HG treated cells to persist in lymphore-
plete mice. Adoptively transferred CD45.1 OT-I CD8+ T-lymphocytes, 
pre-treated with S-2HG, show dramatically enhanced persistence 
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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30 days after transfer (Fig. 4d), expressing elevated CD44, CD127 and 
Bcl-2 levels relative to naïve cells (Fig. 4e)36,37. In response to vacci-
nation with SIINFEKL-loaded dendritic cells, S-2HG-treated OT-I 
CD8+ T-lymphocytes robustly recall (Fig. 4f and Extended Data 
Fig. 6b, c). Consistent with this, OT-I CD8+ T-lymphocytes, pre-treated 
with S-2HG are more proficient at controlling tumour growth in vivo in 
both lymphodepleted (Fig. 4g) and lymphoreplete (Fig. 4h) mice. These 
data demonstrate that S-2HG treatment ex vivo maintains cells in a state 
with increased proliferative and survival capacity, when transferred 
in vivo, that is otherwise decreased by effector differentiation.
S-2HG alters methylation in CD8+ T-cells
mTOR is a modifier of CD8+ T-lymphocyte differentiation; however, 
we do not observe mTOR inhibition36,38 at doses of S-2HG needed 
for this to occur (Extended Data Fig. 7). S-HG treatment ex vivo may 
be selecting cells that express higher levels of anti-apoptotic genes. 
Two critical anti-apoptotic genes implicated in CD8+ T-lymphocyte 
survival are Bcl-2 and Bcl-xl39,40. These genes are not induced by S-2HG 
treatment (Extended Data Fig. 8a-d). Moreover, over-expression of 
Bcl-2 or Bcl-xl (Extended Data Fig. 8e) does not influence the expression 
of CD62L, CD44 or CD127 in the presence or absence of S-2HG 
(Extended Data Fig. 8f-i), indicating that S-2HG is exerting these 
phenotypic changes independently of Bcl-2 or Bcl-xl.
Inhibition of 2-oxoglutarate-dependent dioxygenases that demethylate 
histones (Jumonji C containing proteins) or oxidise 5-methylcytosine 
in DNA (Ten-eleven translocation (Tet) proteins) may mediate S-2HG’s 
effect 32,41-43. S-2HG alters global levels of various histone methylation 
marks (Extended Data Fig. 9a); in particular, di- and tri-methylation 
on H3K27 are reciprocally altered, indicating inhibition of H3K27me3 
demethylation (Fig. 5a, b and Extended Data 9b). The H3K27me2/3 
demethylase, Kdm6a (Utx), is an important regulator of thymocyte 
differentiation44; changes in H3K27me3 levels correlate with genes 
associated with regulation of CD8+ T-lymphocyte differentiation11. 
Global levels of H3K27me3 in CD8+ T-lymphocytes are reduced 
following activation, but remain high with S-2HG treatment in a 
HIF-1α -independent manner (Fig. 5c and Extended Data Fig. 9c). Utx 
is induced following TCR stimulation (Extended Data Fig. 9d) and 
inhibition of Utx reproduces the effect of S-2HG treatment on CD62L 
expression (Fig. 5d and Extended Data Fig. 9e and f). In vivo, levels of 
H3K27me3 are highest in central memory (CD62LHighCD44High) and 
naïve (CD62LHighCD44Low) CD8+ T-lymphocytes, relative to effectors 
(CD62LLowCD44High) (Fig. 5e). To determine if histone methylation 
changes occur at the transcription start site (TSS) of CD62L with S-HG 
treatment, we performed ChIP-PCR for H3K27me3, H3K4me3 and 
RNA pol II, on naïve and activated CD8+ T-lymphocytes cultured 
with or without S-2HG (Fig. 5f and Extended Data Fig. 9g). We could 
find no enrichment for H3K27me3 at or around the TSS. However, 
naïve and S-2HG treated CD8+ T-lymphocytes have higher enrich-
ment for H3K4me3 at the TSS that is reduced in vehicle-treated cells. 
Additionally, S-2HG treated CD8+ T-lymphocytes have markedly 
higher RNA pol II biding than both naïve and vehicle treated cells. Thus 
S-2HG is promoting CD62L transcription directly with enrichment of 
H3K4me3 at the TSS and indirectly via preservation of H3K27me3 
elsewhere in the genome.
Total levels of 5-methylcytosine (5mC) in genomic DNA are 
largely unchanged by TCR triggering (Fig. 6a). However, total  levels 
of 5-hydroxymethylcytosine (5hmC) decrease following TCR trig-
gering (Fig. 6a). 5hmC removal in genomic DNA can occur via  
Tet-mediated oxidation (active) as well as DNA replication 
 (passive)45,46. S-2HG treatment induces small changes in total 5hmC 
and 5mC in a time-dependent manner (Fig. 6b, c); at day 3, there are 
marginally higher levels of 5hmC (statistically non-significant) with no 
changes in 5mC (Fig. 6b, c). This is likely due to decreased prolifera-
tion in the presence of S-2HG (Extended Data Fig 5g). Following sus-
tained treatment, at days 7 and 9, cells have less 5hmC and more 5mC 
(Fig. 6b, c). 5mC changes did not reach statistical significance at any 
time point; changes in 5hmC were statistically significant at day 7 only. 
Nonetheless, the changes at days 7 and 9 are consistent with inhibition 
of Tet proteins in the presence of sustained S-2HG treatment.
Tet2 regulates CD4+ T-lymphocyte function and is inhibited by 
2HG47,48. Knockdown of Tet2 recapitulates the effect of S-2HG on 
CD62L, indicating that Tet2 also contributes to CD8+ T-lymphocyte 
effector differentiation (Fig. 6d and Extended Data Fig. 10a), impli-
cating DNA demethylation as an added epigenetic modifier of CD8+ 
T-cell differentiation12. We performed both 5hmC and 5mC DIP-PCR 
around the TSS of CD62L (Fig. 6e and Extended Data Fig 10b). Naïve 
cells have the highest and lowest enrichment for 5hmC and 5mC 
respectively, while S-2HG treated cells display the opposite pattern. 
Vehicle treated cells have an intermediate level of these two marks.
Discussion
Our data support a model in which both Utx and Tet2 contribute to 
effector differentiation of CD8+ T-lymphocytes in vitro. The activity of 
these epigenetic modifiers is altered by S-2HG in a fashion that inhibits 
effector differentiation.
TCR-triggering induced loss of 5hmC in gDNA, whereas 5mC levels 
were relatively stable (Fig. 6a). 5hmC levels stabilized by 4 days after 
activation (Fig. 6a) and S-2HG treatment produced reciprocal changes 
in 5mC and 5hmC levels at later time points (Fig. 6b, c). We investigated 
5mC and 5hmC presence at and around the TSS of CD62L (Fig. 6e). 
S-2HG treatment causes reciprocal 5mC increases and 5hmC decreases 
in this region consistent with inhibition of Tet proteins and transcrip-
tional repression47, yet there is robust expression of CD62L with S-2HG 
treatment (Fig. 3c, d, e and h and Extended Data Fig. 5m-p). Inhibition 
of Tet2 maintains CD62L expression (Fig. 6d and Extended Data 
Figure 10a), indicating that S-2HG-induced DNA methylation 
changes elsewhere in the genome may indirectly promote CD62L 
expression.
We also investigated H3K4me3 and H3K27me3 patterns at the TSS 
of CD62L (Fig. 5f). S-2HG-treated and naïve CD8+ T-lymphocytes 
have high enrichment for the active H3K4me3 mark49 at the TSS that 
is lost in vehicle-treated cells. At least in S-2HG treated cells, this is 
accompanied by binding of RNA-pol II. Despite global increases in 
H3K27me3 with S-2HG (Fig. 5a-c), the lack of H3K27me3 at the TSS 
of CD62L is not surprising, as this mark is associated with repression49. 
Nevertheless, inhibition of Utx promotes CD62L maintenance (Fig. 5d 
and Extended Data Fig. 9e and f), indicating that H3K27me3 deposi-
tion at other genomic sites can indirectly promote CD62L expression. 
Due to the relationship between histone methylation and other marks 
such as histone acetylation, modulation of the latter may have similar 
effects to those seen with S-2HG treatment50.
Adoptively transferred cells treated with S-2HG ex vivo have an 
increased capacity to proliferate and persist in vivo, with enhanced 
anti-tumour efficacy (Fig. 4), demonstrating a new strategy to improve 
persistence of adoptive cell therapies for cancer. The data presented 
uncover a metabolic-epigenetic axis that controls aspects of T-cell fate. 
Factors regulating endogenous S-2HG levels, such as HIF signalling, 
TCR triggering, L2hdgh activity and potentially others, can alter the 
differentiation of CD8+ T-lymphocytes and thus shape the immune 
response.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Figure 1 | VHL-HIF signalling regulates 2-hydroxyglutarate levels. 
a/ Unsupervised hierarchical clustering and heat map of all detected 
metabolites. b/ PCA of metabolomes. Percentage variance of each PC  
is in parenthesis. c/ Metabolites ranked in order of decreasing p-value.  
d/ 2HG levels in Vhlfl/fl (n = 7), Vhlfl/fldlckcre (n = 4) and Hif1α fl/fl Vhlfl/fl 
dlckcre (n = 4) CD8+ T-lymphocytes activated with α CD3 and α CD28  
antibodies and then cultured in IL-2 for a further 5 days. Each dot 
represents a mouse. e/ 2HG levels in RCC4 and 786-O cells with 
reconstitution of VHL; n = 3. f/ 2HG levels in MEFs with deletion of VHL; 
n = 3. Unpaired t-test (e-f) and one-way ANOVA (d). Error bars denote 
s.d.; ns  =  non-significant, * p < 0.05, * * p < 0.01, * * * p < 0.001.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
AC
CE
LE
RA
TE
D 
AR
TIC
LE
 P
RE
VI
EW
6  |  N A T U R E  |  V O L  0 0 0  |  0 0  M O N T H  2 0 1 6
ARTICLERESEARCH
 6+* 5+*3HUFHQWDJHRIWRWDOSRROG2 2&RQFHQWUDWLRQRI K\GUR[\JOXWDUDWHP0     QV&RQFHQWUDWLRQRI K\GUR[\JOXWDUDWHP02[\JHQ 3HUFHQWDJHRIWRWDOSRRO   2[\JHQ 6+*5+*$PRXQWRIK\GUR[\JOXWDUDWH QPRO FHOOV     ,/Į&'Į&''D\       K&RQFHQWUDWLRQRI K\GUR[\JOXWDUDWHP0  +LIĮIOIO +LIĮJ&RQFHQWUDWLRQRI K\GUR[\JOXWDUDWHP0  +LIĮIOIO +LIĮ QVL  QV&RQFHQWUDWLRQRI K\GUR[\JOXWDUDWHLQVSOHHQȝ0 +LIĮIOIO  +LIĮ  +LIĮIOIO  +LIĮ 6+*5+*
D  'RQRU'RQRU'RQRU'RQRU$PRXQWRIK\GUR[\JOXWDUDWH QPRO FHOOV2[\JHQ ϮϭйKϮ ϭйKϮM P  2[\JHQP P P P P P2[\JHQ&RQWULEXWLRQWRWRWDO+*SRRO P P P P P P8QODEHOOHG >8&@JOXFRVH >8&@JOXWDPLQHO$PRXQWRI6+* QPROSHU FHOOV VK6FUDPEOHVK/GKDVK/GKDN6+*5+*
     
   
E F
(PSW\9HFWRU/GKD)/$*  (PSW\9HFWRU3GN)/$*6+* 5+*QV  QV6+* 5+*$PRXQWRIK\GUR[\JOXWDUDWH QPRO FHOOV +LIĮIOIO  +LIĮ  +LIĮIOIO  +LIĮ K\GUR[\JOXWDUDWHLQXULQH ȝ0P0FUHDWLQLQH 
QV
H I
Figure 2 | Hypoxic induction of 2-hydroxyglutarate depends on HIF-1α 
in CD8+ T-lymphocytes. a/ 2HG in naïve and activated cells, n≥ 4 mice 
per time point. b/ 2HG in cells cultured at 21% or 1% oxygen 48 h; n = 12 
mice. c/ 2HG in cells cultured at 21% (n = 15), 10% (n = 6), 5% (n = 10) 
or 1% (n = 6) oxygen for 48 h. d/ Enantioselective MS for S- and R-2HG. 
e/ 2HG in human cells( n = 4 healthy donors). f/ Enantioselective MS for 
S- and R-2HG from cells in e. g-h/ 2HG in Hif1α fl/fl and Hif1α fl/fl dlckcre (g) 
or Hif2α fl/fl and Hif2α fl/fl dlckcre (h) cells, cultured as in b; n = 4 mice per 
genotype. i/ 2HG in splenic extracts from Hif1α fl/fl (n = 20) and  
Hif1α fl/fl dlckcre (n = 15) mice. j/ 2HG in urine from Hif1α fl/fl (n = 49) 
and Hif1α fl/fl dlckcre (n = 25) mice. k/. S-2HG in cells with shLdha. n = 4 
individual transductions. l/ Ldha-FLAG (n = 6) or Pdk1-FLAG (n = 4) 
over-expression in Hif1α fl/fl dlckcre cells. The dotted line represents S-2HG 
levels in Hif1α fl/fl cells n = 4/6 individual tranductions. m/ 13C-isotopologue 
profile of 2HG in cells cultured as in b; n = 7 mice per condition. Unpaired 
t-test ( i, j). Paired t-test (b, l, m). One-way ANOVA (c, k) and two-way 
ANOVA (g, h). Error bars denote s.d.; each dot in a, b, c, i and j represents a. 
ns  =  non-significant, * p < 0.05, * * p < 0.01, * * * p < 0.001.
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Figure 3 | S-2HG alters phenotypic marker expression of CD8+ 
T-lymphocytes. a/ Media IL-2 levels from S-2HG-treated cells.  
b/ Expression of Il2 mRNA in S-2HG-treated cells. c/ CD62L and  
CD127 expression on from S-2HG-treated OT-I cellsn = 4 mice.  
d/ % CD62LHighCD44Low and % CD62LLowCD44High cells with S-2HG 
treatment. n = 4 mice. e/CD62L expression on cells treated with S-2HG 
and transduced with empty or L2hgdh-FLAG over-epression vectors.  
f/ Representative flow cytommetry plots of KLRG1 vs CD127 (n = 4)  
on cells from e. Associated statistics are shown. g/ S-2HG level in response 
to shRNA against L2hgdh (n = 4). h/ CD62L expression in response to 
L2hgdh knockdown (n = 4). Representative flow cytometry histogram of 
CD62L surface levels is shown on the right. Two-way ANOVA (a, b, e, f). 
One-way ANOVA (c, d, g, h). Error bars denote s.d..Each dot in a, b, e, f, h, 
represents a mouse. ns = non-significant, * p < 0.05, * * p < 0.01,  
* * * p < 0.001. gMFI = geometric mean fluorescence intensity.
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Figure 4 | S-2HG treatment promotes in vivo homeostatic renewal, 
persistence and anti-tumour capacity of transferred cells. a/ Recovery of 
co-transferred CD45.1+ OT-I cells, from spleens (n = 6). b/In vivo CFSE 
levels in cells from a. c/ % of cells in a that divided 0-9 times in vivo.  
d/ Representative flow cytometry plots and associated statistics of 
recovered cells from spleens (n = 6). e/ Representative analysis of cells,  
in d, relative to naïve cells (n = 6). f/ Recovery of co-transferred cells,  
from spleens, lymphnodes and livers of vaccinated mice (n = 6).  
g/ Lymphodepleted mice bearing EG7-OVA tumours treated with no 
T-cells (n = 7) or OT-I cells cultured with (n = 6) or without (n = 6) 
S-2HG. Error bars denote s.e.m. h/ Lymphoreplete mice bearing EG7-OVA 
tumours treated with no T-cells (n = 6) or OT-I cells cultured with (n = 6) 
or without (n = 6) S-2HG. Error bars denote s.e.m. Paired t-test (a, b, f), 
unpaired t-test (d), one-way ANOVA (g, h). Error bars denote s.d. (not in 
g and h). Each dot in a, b, d and f represents a mouse. ns = non-significant, 
* p < 0.05, * * p < 0.01, * * * p < 0.001. gMFI = geometric mean fluorescence 
intensity.
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Figure 5 | S-2HG alters global H3K27me3 in CD8+ T-lymphocytes.  
a/Immunoblot analysis for H3K27me2 and H3K27me3 in cells treated 
with S-2HG. b/ H3K27me3 in OT-I cells treated with S-2HG. n = 6 mice. 
c/ H3K27me3 abundance in Hif1α fl/fl (n = 4) and Hif1α fl/fl dlckcre (n = 4)  
cells treated with S-2HG. d/ CD62L expression by cells with shUtx #3.  
e/In vivo H3K27me3 levels in CD8+ populations. n = 6 mice. f/ ChIP-
qPCR for H3K4me3, H3K27me and RNA pol II around the TSS for 
CD62L. A pool of n = 6 mice was used. Error bars denote s.e.m. One-way 
ANOVA (b, c). Error bars denote s.d. and each dot in c and e represents 
a mouse. ns = non-significant, * p < 0.05, * * p < 0.01, * * * p < 0.001. 
gMFI = geometric mean fluorescence intensity. For immunoblot source 
images, see Supplementary Fig. 1.
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Figure 6 | S-2HG alters global 5hmC and 5mC in DNA of CD8+ 
T-lymphocytes. a/ 5hmC and 5mC in gDNA. n = 4 mice. b/ 5hmC in 
gDNA from cells treated with S-2HG. n = 4 mice. c/ 5mC in gDNA from 
cells treated with S-2HG-. n = 4 mice. d/ CD62L expression on CD8+ 
T-lymphocytes 7 days after transduction with shTet2 #3. e/ DIP-qPCR for 
5mC and 5hmC around the TSS for CD62L. A pool of n = 6 mice was used. 
Error bars denote s.e.m. One-way ANOVA (b and c). Error bars denote  
s.d. and each dot in b and c represents a mouse. ns =  non-significant,  
* p < 0.05, * * * p < 0.001. gMFI = geometric mean fluorescence intensity.
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Extended Data Figure 1 | VHL-HIF-1α regulate central carbon 
metabolism and 2HG levels in CD8+T-lymphocytes. a/ Illustration of 
central carbon metabolism in CD8+ lymphocytes, including glycolysis 
and the tricarboxylic acid cycle, depicting relative levels of detected 
metabolites between Vhlfl/fl (n = 5), Vhlfl/fldlckcre (n = 5) and Hif1α fl/fl  
Vhlfl/fldlckcre (n = 3) CD8+ T-lymphocyte groups. b/ Glucose consumption 
and lactate production in Vhlfl/fl and Vhlfl/fldlckcre CD8+ T-lymphocytes  
7 days after activation with α CD3 and α CD28 antibodies. n = 4 mice per 
genotype from two independent experiments. c/ Immunoblot analysis for 
HIF-1α and LaminB1, using nuclear extracts prepared from Vhlfl/fl and 
Vhl-/- CD8+ T-lymphocytes cultured in 21% oxygen. d/ Rank of metabolite 
loadings in PC1 from PCA. e/ Immunoblot analysis for HIF-1α , HIF-2α 
and β -tubulin, on whole cell extracts prepared from RCC4 and 786-O 
renal cancer cell lines, with and without expression of functional VHL.  
f/ Deletion efficiency of Vhl in Vhlfl/fl MEFs following infection with 
Adeno-Cre virus, n = 3 individual preparations. Accompanying 
immunoblot analysis for HIF-1α and β -tubulin, on whole cell extracts. 
Two-tailed t-test (b), one-way ANOVA for multiple comparisons (a). Error 
bars denote s.d. and each dot represents an individual mouse in a and b. 
* p < 0.05, * * p < 0.01, * * * p < 0.001. For immunoblot source images, see 
Supplementary Fig. 1.
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Total number of cells extracted: 
Amount per cell: 
Volume of CD8+ T-lymphocyte (l): 
Intracellular concentration: 
Total amount of 2HG measured (nmol): 
2.184x106
2.646
2.646 (nmol) / 2.184x106 = 1.21154x10-15 (mol/cell)
5.53656x10-13
1.21154x10-15 / 5.53656 x 10-13 = 2.18825 (mM)
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Extended Data Figure 2 | See next page for caption.
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Extended Data Figure 2 | HIF-1α-dependent metabolic alterations 
underlie S-2HG production in CD8+ T-lymphocytes. a/ Example 
calculation of intracellular 2HG concentration. b/ 1H-NMR analysis 
for 2HG from CD8+ T-lymphocytes cultured as in Fig. 2b. c/ Deletion 
efficiency of Hif1α or Hif2α in CD8+ T-lymphocytes, isolated from 
Hif1αfl/fldlckcre or Hif2αfl/fldlckcre mice. n = 4 mice. d/ Total 2HG levels, 
normalized to viable cell count or protein content, in Hif1α fl/fl and 
Hif1αfl/fldlckcre CD8+ T-lymphocytes cultured as in Fig. 2b. n = 4 mice 
per genotype. e/ Total 2HG levels, normalized to viable cells or protein 
content, in Hif2α fl/fl and Hif2αfl/fldlckcre CD8+ T-lymphocytes cultured as 
in Fig. 2b. n = 4 mice per genotype. f/ Illustration outlining the workflow 
for metabolite extraction, deletion efficiency and viability experiments 
in Hif1αfl/fl, Hif1αfl/fldlckcre, Hif2α fl/fl and Hif2αfl/fldlckcre CD8+ 
T-lymphocytes. Also shown are viability measurements at day 4.  
n = 4 mice per genotype. g/ Total amount of 2HG in Hif1α fl/fl (n = 6) 
and Hif1αfl/fldlckcre (n = 7) CD8+ T-lymphocytes, at indicated times 
following activation. n ≥ 4 mice per time point. h/ Heat map indicating 
qPCR measurement of expression of enzymes involved in central 
carbon metabolism in CD8+ T-lymphocytes cultured as in Fig. 2b; n = 4 
mice per condition. i/ LC-MS/MS quantification of total intracellular 
succinate, fumarate and malate levels in CD8+ T-lymphocytes isolated 
from C57BL/6J mice and cultured as in Fig. 2b; n = 7 mice. j/ Heat map 
indicating qPCR measurement, in Hif1α fl/fl (n = 4) and Hif1αfl/fldlckcre 
(n = 3) CD8+ T-lymphocytes growing in 1% oxygen, of expression 
of enzymes implicated in the hypoxic production of S-2HG. k/ qPCR 
validation of shRNA-knockdowns in CD8+ T-lymphocytes isolated from 
C57BL/6J mice. l/ LC-MS/MS quantification of S- and R-2HG in CD8+ 
T-lymphocytes isolated from C57BL/6J mice, with shRNA-mediated 
knockdown of Mdh1; n = 4 pools of 4 mice per pool. m/ LC-MS/MS 
quantification of S- and R-2HG in CD8+ T-lymphocytes isolated from 
C57BL/6J mice, with shRNA-mediated knockdown of Mdh2; n = 4 pools 
of 4 mice per pool. n/ LC-MS/MS quantification of R-2HG in CD8+ 
T-lymphocytes isolated from C57BL/6J mice, with shRNA-mediated 
knockdown of Ldha; n = 4 pools of 4 mice per pool. o/ Validation of Pdk1-
FLAG and Ldha-FLAG expression in Hif1αfl/fldlckcre CD8+ T-lymphocytes 
by immunoblot analysis for FLAG. p/ LC-MS/MS quantification of total 
intracellular glutamate levels in CD8+ T-lymphocytes cultured as in 
Fig. 2b; n = 7 mice. q-r/ LC-MS/MS quantification of total intracellular 
glutamate levels in Hif1α fl/fl, Hif1αfl/fldlckcre, Hif2α fl/fl and Hif2αfl/fldlckcre 
CD8+ T-lymphocytes cultured as in Fig. 2b; n = 4 mice per genotype.  
s/ Immunoblot of cytosolic fractions for phospho-PDH E1α (S232) 
and total PDH-E1α in CD8+ T-lymphocytes cultured in 1% oxygen in 
the presence of the indicated concentration of DCA for 48h. t/ Total 
intracellular concentration of 2HG in CD8+ T-lymphocytes from 
C57BL/6J mice cultured as in Fig. 2b and treated with 5 mM DCA for the 
latter 48h of culture; n = 4 mice. u/ Total intracellular amount of 2HG, 
nomralized to viable cell count or protein content in CD8+ T-lymphocytes 
from C57BL/6J mice cultured as in Fig. 2b and treated with 5 mM DCA 
for the latter 48h of culture; n = 4 mice. v/ Total intracellular amount of 
glutamate in CD8+ T-lymphocytes from C57BL/6J mice cultured as in 
Fig. 2b and treated with 5 mM DCA for the latter 48 h of culture; n = 4 
mice. Two-way ANOVA for grouped data (d, e, f, q, r, t, u, v). Paired t-test 
for matched comparisons (i, p), one-way ANOVA for multiple matched 
comparisons (g, l, m, n). Error bars denote s.d. and each dot represents an 
individual mouse in g, i and p. ns =  non-significant, * p < 0.05, * * p < 0.01, 
* * * p < 0.0001. Experiments were performed with indicated numbers 
of mice from multiple occasions. For immunoblot source images, see 
Supplementary Fig. 1.
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0
Addition of IL-2.
Culture in 21% or 1% O2.
2 4
Harvest gDNA. 
a
Extended Data Figure 3 | Naïve and expanding primary CD8+ 
T-lymphocytes do not possess mutations in Idh1 or Idh2 that can 
explain the presence of high levels of 2HG. a/ Illustration outlining the 
workflow for mutational analysis of Idh1 and Idh2 b/ Sanger sequencing 
chromatograms validating the presence of wild type Idh1 as compared 
to the C57BL/6J NCBI reference sequence. c/ Alignment of mouse and 
human IDH1 protein indicating conservation of active site arginine 
residues. d/ Sanger sequencing chromatograms validating the presence of 
wild type Idh2 as compared to the C57BL/6J NCBI reference sequence.  
e/ Alignment of mouse and human IDH2 protein indicating conservation 
of active site arginine residues.
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Extended Data Figure 4 | Kinetics of 2HG labelling in 21% and 1% 
oxygen, by U-13C-glucose and U-13C-glutamine. a/ Proposed mechanism 
by which HIF-1α controls S-2HG production in CD8+T-lymphocytes  
and 13C-labelling strategy using U-13C-glucose (m+ 6) and U-13 
C-glutamine (m+ 5) to label endogenous 2HG. Red and green represent 
pathways promoted and inhibited respectively by HIF-1α in hypoxia.  
b/ Isotopologue distribution of 2HG (as a percentage of the total pool)  
in CD8+ T-lymphocytes, after labelling with U-13C-glucose for 1, 5 and 
24 h in both 21% and 1% oxygen conditions; n = 3 mice per time point. 
Error bars denote s.d. c/ Isotopologue distribution of 2HG (as a percentage 
of the total pool) in CD8+ T-lymphocytes, after labelling with U-13C-
glutamine for 1, 5 and 24 h in both 21% and 1% oxygen conditions; n = 3 
mice per time point. Error bars denote s.d.
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Extended Data Figure 5 | See next page for caption.
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Extended Data Figure 5 | S-2HG treatement promotes HIF-1α  
stability and alters the phenotypic and functional properties of  
CD8+ T-lymphocytes in a HIF-1α-independent manner.  
a-b/ Immunoblot analysis of nuclear and cytosolic fractions, prepared 
from CD8+ T-lymphocytes cultured in (a) 21% and (b) 1% oxygen, for 
HIF-1α , HDAC1, phospho-PDH E1α (S232) and total PDH-E1α .  
Cells were activated for 48 h with α CD3+ α CD28 antibodies and 
then expanded for a further 4 days in the presence of IL-2 followed by 
treatment with the indicated concentration of S-2HG for 16 hours. The 
arrow indicates HIF-1α protein. c/ Glucose consumption and lactate 
production of C57BL/6J, Hif1α fl/fl (n = 12) and Hif1αfl/fldlckcre (n = 4) 
CD8+ T-lymphocytes treated with or without 500 μ M S-2HG-octyl ester 
for 16 hours as in Extended Data Fig. 5a. d/ VEGF-A production of 
wild type C57BL/6J, Hif1α fl/fl (n = 16) and Hif1αfl/fldlckcre (n = 4) CD8+ 
T-lymphocytes treated with or without 500 μ M S-2HG-octyl ester for 
16 hours as in Extended Data Fig. 5a. e/ Representative flow cytometry 
plots of IFN-γ vs TNF-α in SIINFEKL re-stimulated OT-I CD8+ 
T-lymphocytes, as a function of increasing doses of S-2HG-octyl ester  
for 7 days. Associated quantification and statistics are shown in the  
graphs below. f/ Specific killing of EG7-OVA cells by OT-I CD8+ 
T-lymphocytes. Total splenocytes were activated for 48 h with 1000 nM 
SIINFEKL and then expanded for a further 4 days in the presence of  
IL-2 followed by treatment with 500 μ M S-2HG-octyl ester for 24 h. OT-I 
CD8+ T-lymphocytes were incubated with target and control cells for  
4 hours; n = 3 mice per condition. g/ CFSE dilution assay, with associated 
statistics (n = 4 mice per condition) at day 3 of CD8+ T-lymphocytes 
activated with α CD3+ α CD28 antibodies and cultured with or without 
500 μ M S-2HG-octyl ester from day 0. Data are representative of 4 mice. 
Associated quantification and statistics are shown in the graph on the 
right. h/ Viability and annexin V assay of CD8+ T-lymphocytes treated 
with increasing S-2HG doses for 4 days, n = 4 mice. i/ Viability of CD8+ 
T-lymphocytes cultured with 300 μ M S-2HG-octyl ester for the indicated 
number of days, n = 4 mice. j/ Amount of IFN-γ protein in the media 
of wild type C57BL/6J, Hif1α fl/fl (n = 8) and Hif1α fl/fl dlckcre (n = 4) 
CD8+ T-lymphocytes treated for 24 h with or without 500 μ M S-2HG-
octyl ester. k/Viability of Hif1α fl/fl (n = 8) and Hif1α fl/fl dlckcre (n = 4) 
OT-I CD8+ T-lymphocytes activated with 1000 nM SIINFEKL peptide 
and cultured for 7 days with or without 500 μ M S-2HG-octyl ester in 
the absence of IL-2 supplementation from day 0. l/ Expression of Ifng 
mRNA in CD8+ T-lymphocytes treated for either 24 h or 7 days with or 
without 500 μ M S-2HG-octyl ester. n = 4 mice per group. m/ CD44 and 
CD62L surface expression on OT-I CD8+ T-lymphocytes treated with 
increasing doses of S-2HG for 7 days. Cells were activated with 1000 nM 
SIINFEKL peptide; n = 3 mice. Gated on live, CD8+ cells. n/ Illustration 
outlining the workflow for the experiment. Left panel: %CD62LHigh 
CD8+ T-lymphocytes, treated for 7 days with 500 μ M S-2HG-octyl ester, 
followed by washout or maintenance of the compound and follow up 
every 3rd day, for 9 more days; n = 4 mice. Right panel: %CD62LHigh CD8+ 
T-lymphocytes, treated for 7 days with vehicle, followed by addition of 
500 μ M S-2HG-octyl ester or vehicle and follow up every 3rd day, for  
9 more days; n = 4 mice. Gated on live, CD8+ cells. o/ CD44 and CD62L 
surface expression on Hif1α fl/fl and Hif1α fl/fl dlckcre CD8+ T-lymphocytes 
treated with or without 500 μ M S-2HG-octyl ester for 1, 7 and 10 days 
following treatment. Data are representative of 3 mice per genotype. Gated 
on live, CD8+ cells. p/ CD44 and CD62L surface expression on Hif2α fl/fl  
and Hif2α fl/fl dlckcre CD8+ T-lymphocytes treated with or without 500 μ M  
S-2HG-octyl ester for 1, 7 and 10 days following treatment. Data are 
representative of 2 mice per genotype. Gated on live, CD8+ cells. q/ Flow 
cytometric characterisation of indicated phenotypic markers on Hif1α fl/fl  
(n = 4) and Hif1α fl/fl dlckcre (n = 4) CD8+ T-lymphocytes treated for  
7 days with 500 μ M S-2HG-octyl ester. Gated on live CD8+ cells.  
r/ Validation of L2hgdh-FLAG expression in CD8+ T-lymphocytes from 
C57BL/6J mice by immunoblot analysis for FLAG. The arrow indicates 
L2hgdh-FLAG protein. s/ qPCR validation of L2hgdh knockdowns in 
CD8+ T-lymphocytes isolated from C57BL/6J mice. t/ CD127 surface 
expression in response to L2hgdh knockdown (n = 4). Representative flow 
cytometry histogram of CD127 surface levels on transduced (GFP+)  
CD8+ T-lymphocytes in response to shScramble or shL2hgdh #3 in 21% or 
1% oxygen is shown on the right. u/qPCR quantification of Prdm1,  
Sell, Eomes, Tcf7, Bcl6 and Ccr6 expression in CD8+ T-lymphocytes  
treated for 1 or 7 days with or without 500 μ M S-2HG-octyl ester. Paired 
t-test for matched comparisons (g) and two-way ANOVA for grouped  
data (c, d, j, k, l, q). One-way ANOVA for multiple comparisons  
(i, n, t). Error bars denote s.d. and each dot in c, d, g, j, k, l, q, t represents 
an individual mouse. ns = non-significant, * p < 0.05, * * p < 0.01,  
* * * p < 0.001. gMFI = geometric mean fluorescence intensity. Experiments 
were performed with indicated numbers of mice from multiple occasions. 
For immunoblot source images, see Supplementary Fig. 1.
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Extended Data Figure 6 | Ex vivo treatment of CD8+ T-lymphocytes 
with S-2HG promotes in vivo homeostatic proliferation and recall 
of adoptively transferred cells. a/ Diagram outlining the homeostatic 
proliferation experiments in Figure 4a-c. Representative flow cytometry 
plots are shown for each pool before and after adoptive transfer. Flow 
cytometry plots show viable CD8+ cells. b/Diagram outlining the recall 
experiments in Figure 4f. c/ Representative flow cytometry plots of 
recalling CD45.1+ CD8+ T-lymphocytes in indicated organs on day 7 post 
vaccination (day 37 post transfer).
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Extended Data Figure 7 | S-2HG does not inhibit mTOR signalling 
at the doses necessary for the formation of memory-like CD8+ 
T-lymphocytes. Immunoblot analysis on cytosolic extracts for mTOR 
signalling in CD8+ T-lymphocytes treated with the indicated doses of 
S-2HG for 24 h. For immunoblot source images, see Supplementary Fig. 1.
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Extended Data Figure 8 | S-2HG does not induce Bcl-2 or Bcl-xl that 
can explain the in vivo persistence of adoptively transferred CD8+ 
T-lymphocytes. a/qPCR quantification of Bcl2 and Bclxl mRNA levels in 
response to 500 μ M S-2HG-octyl ester treatment for either 1 or 7 days.  
n = 4 mice. b/Immunnoblot analysis for Bcl-2 and Bcl-xl protein in 
response to increasing doses of S-2HG-octyl ester for 9 days. c/qPCR 
quantification of Bcl2 and Bclxl mRNA levels in response to 300 μ M  
S-2HG-octyl ester treatment for either 1, 7 or 9 days. n = 4 mice.  
d/Representative flow cytometry histograms of Bcl-2 and Bcl-xl 
abundance in CD8+ T-lymphocytes treated with 300 μ M S-2HG-octyl 
ester for 9 days. Quantification and associated statistics are shown in 
the graph on the right. n = 3 mice. e/Immunoblot analysis confirming 
the expression of Bcl-xl-FLAG and Bcl-2-FLAG in OT-I in CD8+ 
T-lymphocytes. f-h/CD62L (f), CD127 (g) and CD44 (h) surface 
expression in OT-I CD8+ T-lymphocytes transduced with retrovirus 
expressing either Bcl-2-FLAG or Bcl-xl-FLAG and treated with the 
indicated concentration of S-2HG-octyl ester for 7 days. n = 2 mice. 
i/ Representative flow cytometry histograms of CD62L, CD127 and 
CD44 surface expression in OT-I CD8+ T-lymphocytes transduced with 
retrovirus expressing either Bcl-2-FLAG or Bcl-xl-FLAG and treated 
with the indicated concentration of S-2HG-octyl ester for 7 days. The 
associated statistics of these flow cytometry data are shown in f, g and h. 
* * P < 0.01, ns =  non-significant. Paired t-test for matched comparisons 
(d) and two-way ANOVA for grouped data (a, b). One-way ANOVA of 
matched samples for multiple comparisons (c, f, g, h). Error bars denote 
s.d. and each dot in a and c represents an individual mouse. ns = non-
significant, * * p < 0.01, gMFI = geometric mean fluorescence intensity. 
Experiments were performed with indicated numbers of mice from at least 
two occasions. For immunoblot source images, see Supplementary Fig. 1.
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Extended Data Figure 9 | S-2HG induces global histione H3 
methylation changes in CD8+ T-lymphocytes. a/ Immunoblot analysis 
on nuclear extracts for histone H3 methylation marks in activated CD8+ 
T-lymphocytes treated with the indicated doses of S-2HG for 7 days.  
b/Representative flow cytometry histograms of H3K27me3 staining as a 
function of increasing S-2HG-octyl ester concentration. c/ H3K27me3 
staining in CD8+ T-lymphocytes treated with or without 500 μ M S-2HG-
octyl ester and stained with or without fluorophore conjugated C36B11 
antibody. d/ qPCR measurement for expression of Utx in unstimulated 
and stimulated CD8+ T-lymphocytes; n = 4 mice. Expression for Utx is 
displayed for each mouse individually. e/ Represetative flow cytomery 
plots of CD44 vs CD62L expression, with associated statistics, on  
activated CD8+ T-lymphocytes after 4 days of treatment with 500 μ M 
S-2HG-octyl ester or 1 μ M GSKJ4. Gated on live, CD8+ cells. n = 3 mice.  
f/ Representative flow cytometry plots of CD44 vs CD62L expression  
on CD8+ T-lymphocytes with shRNA-mediated knockdown of Utx,  
7 days after trasnduction. Gated on live, CD8+GFP+ cells. Graph on right 
shows knockdown hairpin fidelity for Utx. g/ IgG control ChIP-qPCR for 
H3K4me3, H3K27me and RNA pol II at and around the TSS for CD62L, 
in freshly isolated naïve or activated CD8+ T-lymphocytes treated with 
or without 500 μ M S-2HG-octyl ester for 7 days. Each profile shows the 
fold change over the non-binding control primer. Each dot represents an 
individual primer pair. A pool of n = 6 mice was used for each condition. 
Error bars denote s.e.m. One-way ANOVA for multiple matched 
comparisons (e). Each dot in c represents an individual mouse. Error 
bars denote s.d. * * p < 0.01. Experiments were performed with indicated 
numbers of mice from at least two occasions. For immunoblot source 
images, see Supplementary Fig. 1.
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Extended Data Figure 10 | S-2HG induces global changes in the content 
of 5hmC and 5mC in genomic DNA of CD8+ T-lymphocyte genomic 
DNA. a/ Representative flow cytometry plots of CD44 vs CD6L expression 
on CD8+ T-lymphocytes with shRNA-mediated knockdown of Tet2, 7 
days after trasnduction. Gated on live, CD8+GFP+ cells. Graph on right 
shows knockdown hairpin fidelity for Tet2. b/ IgG control DIP-qPCR 
for 5mC and 5hmC at and around the TSS for CD62L, in freshly isolated 
naïve or activated CD8+ T-lymphocytes treated with or without 500 μ M 
S-2HG for 7 days. Each profile shows the fold change over the non-binding 
control primer. Each dot represents an individual primer pair. A pool of 
n = 6 mice was used for each condition. Error bars denote s.e.m.
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